Abpro Holdings, INC Form 4 insider transactions

Abpro Holdings, Inc. Director Soo Young Lee was granted 60,600 stock options with an exercise price of $0.3154.

Abpro Holdings, Inc. CEO and Chairman Miles Suk acquired 72,035 shares of common stock at an average price of $0.28 per share.

Abpro Holdings, Inc. Director and 10% Owner Anthony D. Eisenberg was granted 60,600 stock options with an exercise price of $0.3154 per share, vesting fully on November 13, 2025.

Abpro Holdings, Inc. CEO and Chairman, Suk Jin Wook (Miles), acquired 500,000 Restricted Stock Units, increasing his beneficial ownership to 646,477 shares.

Abpro Holdings CEO and Chairman Suk Jin Wook (Miles) reports the acquisition of 16,200 shares of common stock at an average price of $0.26 per share.

Abpro Holdings CEO Suk Jin Wook (Miles) reports the purchase of 4,325 shares of common stock at a weighted average price of $0.25 per share.

Abpro Holdings CEO Suk Jin Wook (Miles) reports purchasing common stock in two transactions on April 23 and 24, 2025.

Abpro Holdings Co-CEO and Chairman, Suk Jin Wook, reports the acquisition of 613,500 stock options, which were inadvertently omitted from a previous filing.

Abpro Holdings CEO Ian Chan received a significant number of shares and stock options as part of the company's recent business combination.

Abpro Holdings Co-CEO, Suk Jin Wook, acquired 91,900 shares of common stock as part of the company's recent business combination.

Abpro Holdings' Chief Medical Officer, Robert J. Markelewicz Jr., was granted multiple stock option awards as part of the company's recent business combination.

Atlantic Coastal Acquisition Corp. II (ACAB) filed a Current Report on Form 8-K to correct a typographical error in previous filings related to its proposed business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) has entered into a Forward Purchase Agreement with YA II PN, LTD. for up to 500,000 shares in connection with its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) announces stockholder approval of all proposals related to its business combination with Abpro Corporation at a special meeting held on November 7, 2024.

Atlantic Coastal Acquisition Corp. II entered into a non-redemption agreement with an investor to retain up to 124,352 shares, aiming to reduce redemptions in connection with its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. for up to $50 million in newly issued shares of common stock, contingent upon the closing of its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II received a delisting notice from Nasdaq for failing to meet listing requirements and is requesting a hearing while extending the deadline for its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) has filed an amendment to its Registration Statement on Form S-4 regarding its proposed business combination with Abpro Corporation, including a revised investor presentation.

Atlantic Coastal Acquisition Corp. II amends its business combination agreement with Abpro Corporation, issuing shares to its sponsor in lieu of $2 million in unpaid expenses.

Atlantic Coastal Acquisition Corp. II (ACAB) has entered into subscription agreements with Abpro Bio International Inc. and Celltrion, Inc. for a total of $11.2 million in PIPE financing to support its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) has entered into an expense advancement agreement with its sponsor for up to $600,000 to cover working capital and expenses related to its proposed business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II received notification from Nasdaq regarding non-compliance with listing rules due to insufficient publicly held shares and market value, but expects to resolve the issue through its proposed business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II (ACAB) has filed an amendment to its Registration Statement on Form S-4 regarding its proposed business combination with Abpro Corporation, a biopharmaceutical company developing antibody therapies.

Abpro, a next-generation antibody company, is set to go public through a $500 million business combination with Atlantic Coastal Acquisition Corp. II, aiming to advance its clinical programs and expand its portfolio.